Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort - Determinants and Consequences.
Johanna I LutterRudolf A JoerresFranziska C TrudzinskiPeter AlterChristina KellererHenrik WatzTobias WelteRobert BalsDiego Kauffmann-GuerreroJürgen BehrRolf HolleClaus F VogelmeierKathrin Kahnertnull nullPublished in: International journal of chronic obstructive pulmonary disease (2021)
ICS therapy in COPD GOLD A/B patients can have small positive and negative effects on clinical outcomes and health care costs, indicating that the clinical evaluation of ICS over-therapy in COPD requires a multi-dimensional approach.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- healthcare
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- cystic fibrosis
- prognostic factors
- patient reported outcomes
- bone marrow
- silver nanoparticles
- social media
- replacement therapy
- cell therapy
- patient reported
- smoking cessation